Payment overview · 2025
General Payments
$181.51
9 reported records · 7 companies
Healthcare provider profile · identity verified
Natasha Mae Loftin
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LEXINGTON, TN · NPI 1740551613
Verified facts
What the public records show
CMS Open Payments records show Natasha Mae Loftin received $181.51 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.10 | 30.4% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $23.55 | 13.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.55 | 13.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.33 | 11.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.24 | 11.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.24 | 10.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.50 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.51 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 186 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
186 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 92 |
| Gabapentin | Gabapentin | 364 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 75 |
| Lisinopril | Lisinopril | 297 | 82 |
| Omeprazole | Omeprazole | 282 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 58 |
| Metformin Hcl | Metformin Hcl | 233 | 60 |
| Furosemide | Furosemide | 212 | 58 |
| Losartan Potassium | Losartan Potassium | 202 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 39 |
| Eliquis | Apixaban | 199 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 186 | 34 |
| Potassium Chloride | Potassium Chloride | 185 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 28 |
| Meloxicam | Meloxicam | 169 | 46 |
| Famotidine | Famotidine | 160 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 47 |
| Simvastatin | Simvastatin | 159 | 44 |
| Tramadol Hcl | Tramadol Hcl | 157 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 45 |
| Carvedilol | Carvedilol | 139 | 32 |
| Alprazolam | Alprazolam | 122 | 16 |
| Farxiga | Dapagliflozin Propanediol | 121 | 22 |
| Sertraline Hcl | Sertraline Hcl | 119 | 29 |
| Alendronate Sodium | Alendronate Sodium | 107 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 26 |
| Trazodone Hcl | Trazodone Hcl | 87 | 23 |
| Azithromycin | Azithromycin | 83 | 67 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 81 | 12 |
| Pregabalin | Pregabalin | 81 | 12 |
| Jardiance | Empagliflozin | 77 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 17 |
| Clonazepam | Clonazepam | 70 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 17 |
| Buspirone Hcl | Buspirone Hcl | 66 | 20 |
| Spironolactone | Spironolactone | 65 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 60 | suppressed |
| Cefdinir | Cefdinir | 57 | 51 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 11 |
| Donepezil Hcl | Donepezil Hcl | 56 | suppressed |
| Ozempic | Semaglutide | 54 | 14 |
| Allopurinol | Allopurinol | 53 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 20 |
| Ezetimibe | Ezetimibe | 51 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Rybelsus | Semaglutide | 50 | suppressed |
| Cilostazol | Cilostazol | 48 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 16 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Qtern | Dapagliflozin/Saxagliptin Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.51 · 9 records | GlaxoSmithKline, LLC. | GVOKE HYPOPEN, General - Therapies, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, XYOSTED | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error